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Summary 
Many prison inmates use opioids before incarceration and relapse rates upon prison release 
are high. Methadone maintenance has become the principal treatment modality for opioid 
addiction and it is increasingly implemented in criminal justice settings. More treatment 
options that can be initiated during incarceration and continued in the community are needed. 
Naltrexone implants constitute a novel treatment that has not been evaluated in a prison 
setting. Naltrexone implants have not been compared to opioid maintenance in a prospective 
study. A systematic literature review has been lacking.  
 
In this thesis, the findings from a systematic literature review on sustained-release naltrexone, 
and the outcomes from a randomised-controlled trial (RCT) on naltrexone implants and 
methadone among pre-release prison inmates with heroin dependence are reported. Further, 
effects of illicitly used opioids during naltrexone implant treatment are described.  
 
In the systematic literature review only one RCT of naltrexone depot for opioid dependence 
was found that met the inclusion criteria for assessment of treatment effectiveness. In that 
trial, Comer and colleagues reported a greater reduction in heroin use by a 384 mg naltrexone 
depot compared to a 192 mg depot or placebo injections. Although this indicates the 
effectiveness of naltrexone depot for opioid dependence, the overall evidence was found to be 
insufficient. 
 
The prison study met several research challenges related to the criminal justice setting and the 
transition from prison to the community. These were related to interest and motivation during 
incarceration, random treatment allocation of inmates and aftercare following prison release. 
In spite of these challenges, the study found naltrexone implants and methadone to be of 
comparable effectiveness. Both treatments reduced heroin and illicit benzodiazepine use, and 
criminal activity during the six months after prison release. The reductions were found in the 
intention-to-treat analyses of all 44 participants and they were supported by the completer 
analyses. Subsequent analyses of opioid effects during naltrexone treatment revealed a larger 
than expected proportion of patients who had used opioids in spite of blood levels indicating 
satisfactory naltrexone release. 
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The findings from the prison study indicate that offering naltrexone implants to pre-release 
inmates is feasible and that this novel treatment is likely to reduce heroin use. If opioids are 
used during implant treatment their expected reinforcing effects are usually lacking. 
 
Sammendrag [Norwegian] 
Mange fengselsinnsatte bruker opiater før soning og det er høye rater av tilbakefall etter 
løslatelse. Metadon vedlikehold har blitt den mest vanlige behandlingsformen for 
heroinavhengighet og er i økende grad tilgjengelig under soning. Det er behov for flere 
behandlingsformer som kan påbegynnes i fengsel og fortsettes etter løslatelsen. Naltrekson 
implantater er en ny behandlingsmåte som hittil ikke har vært undersøkt i en fengselsetting. 
Naltrekson implantater har heller ikke blitt sammenlignet med vedlikeholdsbehandling i en 
prospektiv studie. En systematisk litteraturgjennomgang har ikke vært gjort. 
 
I denne avhandlingen rapporteres det funn fra en systematisk litteraturgjennomgang på 
langtidsvirkende naltrekson. Dessuten rapporteres resultatene fra en randomisert kontrollert 
studie av naltrekson implantater sammenlignet med metadon vedlikehold blant 
heroinavhengige innsatte som løslates fra fengsel. Effekten av illegalt brukte opiater under 
naltrekson implantat behandling er også beskrevet. 
 
Ved den systematiske litteraturgjennomgangen fant vi kun én randomisert kontrollert studie 
på naltrekson depot i behandling av opiatavhengighet som kunne inkluderes for evaluering av 
behandlingseffekt. I studien fant Comer og medarbeidere en større reduksjon i heroinbruk hos 
de som ble behandlet med 384 mg naltrekson depot sammenlignet med 192 mg eller placebo 
sprøyter. Til tross for at det ble funnet en fordelaktig effekt av naltrekson depot i behandling 
av heroinavhengighet, ble den samlete evidensen vurdert som utilstrekkelig.  
 
Fengselsstudien viste spesifikke utfordringer vedrørende interesse og motivasjon under 
soning, tilfeldig fordeling av innsatte til behandling og oppfølging etter soning. Til tross for 
disse utfordringene kunne studien vise at naltrekson implantat behandling og metadon 
vedlikeholdsbehandling har sammenlignbar effekt. Begge behandlingsformene reduserte 
heroin- og benzodiazepinbruk og kriminalitet ved oppfølging seks måneder etter løslatelsen. 
Dette gjaldt blant alle 44 deltagerne uavhengig om de startet behandling eller ikke og funnene 
ble støttet av analysen av deltakerne som fullførte studien. En senere analyse av opiatbruk 
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under naltrekson implantat behandling viste at en større andel enn forventet hadde brukt 
opiater til tross for tilfredsstillende nivå av naltrekson i blodet. 
 
Funnene fra fengselsstudien viser at det lar seg gjøre å tilby naltrekson implantat behandling 
før løslatelse og at denne behandlingen reduserer heroinbruk. Dersom opiater brukes under 
behandlingen vil den forventete ruseffekten oftest utebli. 
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1. Introduction 
1.1. Drug use and the prison setting 
Heroin is the most commonly abused opioid and in the European Union an estimated 1.3 to 
1.7 million individuals (about 0.5% of the adult population) are considered problem opioid 
users (EMCDDA 2008). Good prevalence data are difficult to obtain, but the United Nations 
Office on Drugs and Crime estimates similarly low opioid use prevalence of approximately 
0.6% for the USA and of 0.25% when the whole world’s population is considered (UNODC 
2008). Although affecting a relatively small group of the general population, the impact of 
illicit heroin use on the addicted individuals, their families and the community is often 
devastating.  
 
The relationship between illicit drug use and criminality is well established (Sinha & Easton 
1999). In inmate populations throughout the world substance abuse disorders are 
overrepresented compared to the general population (Fazel et al. 2006). In the Netherlands, as 
many as 79% of inmates report drug use before incarceration (EMCDDA 2007) and similar 
rates are reported for the USA with ca. 70% (Mumola & Karberg 2006) and for Norway with 
between 60 and 70% (Friestad & Hansen I.L. 2005; Ødegård 2008). During incarceration, 
drug-involved offenders are likely to reduce the frequency of use and to change their 
preferred drug of abuse compared to outside of prison (Plourde & Brochu 2002; Shewan et al. 
1994). The most frequently used drugs in prison are cannabis, followed by stimulants, 
benzodiazepines and opioids (Simpler & Langhinrichsen-Rohling 2005). In- and outside of 
prison, heroin users take a prominent part, because daily heroin use quickly leads to 
dependence with unpleasant withdrawal upon discontinuation. Maintaining daily heroin use is 
expensive, and hence often followed by acquisitive crime. Consequently, penal reactions are 
almost inevitable. Most heroin addicted offenders will be incarcerated at least once during 
their lifetime and a considerable number of them repeatedly (Dolan et al. 2005; Milloy et al. 
2008). Thus, the criminal justice facilities are likely to become a stable institution in their 
otherwise rather disorganized lives. Incarceration provides stability for many individuals who 
fail to adapt to ordinary lifestyles when outside of prison. For heroin addicts, incarceration 
implies a major behaviour change. They are either forced to detoxify, or they continue 
injecting with high risk of acquiring blood borne diseases such as HIV and high risk of 
overdose, because access to syringe exchange programmes is limited and heroin or other 
illicit opioids are not continuously available (Lines et al. 2006a). Following prison release, 
many heroin-involved inmates will relapse within the first few months (Kinlock et al. 2002; 
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Nurco et al. 1991). During this time, the risk of overdose death is particularly high (Seaman et 
al. 1998; Ødegård et al. 2010).  
 
Heroin-addicted offenders often circulate between the community, with daily drug use and 
subsequent acquisitive crime, and incarceration with forced abstinence or limited access to 
drugs. Thus, heroin addiction becomes a vicious circle for inmates and treatment providers. If 
inmates achieve abstinence during incarceration, they often fail to maintain it after prison 
release; and prison health services and community treatment providers have to re-define their 
positions continuously in order to facilitate recovery. Outside of prison the addicted individual 
may be largely unavailable for treatment, whereas during incarceration help including housing 
may be a clearly stated claim.  
 
The unanimous conclusion of several reviews on criminal justice based treatment is that 
access to specialized addiction treatment services in prisons is seriously limited and that 
further programme evaluations are urgently needed (Cropsey et al. 2005; Pearson & Lipton 
1999; Perry et al. 2006). These reviews also find that prison-based therapeutic communities 
(TC) that provide continuity of care after release have shown beneficial effects. Five year 
follow-up data for 576 TC participants in a US study show reduced drug relapse and criminal 
recidivism (Prendergast et al. 2004). In Norway, the Tyrili foundation provides treatment for 
incarcerated drug addicts (Johansen 2005). In Oslo, Tyrili applicants spend nine months in a 
prison-based therapeutic community and after release they are offered to continue in a TC 
outside of prison.  
 
Drug-involved inmates wanting to initiate treatment during incarceration will often have to 
make an extra effort; because there are fewer treatment options in prison compared to the 
community and because the capacity of prison-based treatment seldom meets the demand. To 
initiate treatment however, incarceration may offer extraordinary possibilities such as a highly 
structured environment and reduced availability of illicit and prescription drugs. Large scale 
initiatives to substantially improve treatment possibilities in criminal justice settings are 
currently being undertaken (Wexler & Fletcher 2007). 
 
Opioid maintenance therapy (OMT), which has been shown to be effective in community 
settings, is still controversial in criminal justice settings. Although OMT is made increasingly 
available in European prisons (Stover et al. 2004), access is far from optimal or even lacks 
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completely in many parts of the world (Larney & Dolan 2009; Stallwitz & Stover 2007). 
Restricted access to OMT during incarceration includes highly developed countries such as 
the USA with a per capita prison population that is about 10-fold larger compared to Norway 
(UNDP 2009). However, a randomised-controlled trial suggested already in the 1960s that 
methadone maintenance (MMT) is effective to prevent relapse when initiated before prison 
release (Dole et al. 1969). Although prison-based methadone maintenance is available in a 
few US penal facilities (Tomasino et al. 2001), the next RCT on methadone maintenance 
conducted in the US criminal justice setting was reported only a few years ago (Kinlock et al. 
2007). After several years of preparation, the criminal justice system in Baltimore finally 
approved conducting this trial (Prendergast 2009). In this RCT, heroin addicted inmates were 
randomly allocated to one of three groups: methadone start and counselling before release, 
referral to methadone treatment after release or counselling only. At one month follow up the 
methadone-before-release group was more likely to continue in community treatment and 
more likely to provide opioid negative urine tests. This study will be followed up by a larger 
multi-centre trial involving sites in several US American States and by another trial that 
evaluates the effects of buprenorphine. 
 
A multicentre trial on sustained-release naltrexone to prevent relapse after prison release has 
also been suggested (O'Brien & Cornish 2006). Today, two RCTs evaluating oral naltrexone 
for criminal justice populations have been conducted (Cornish et al. 1997; Shearer et al. 
2007). Two other non-randomised trials on oral naltrexone are reported (Brahen et al. 1984; 
Chan 1996). The Australian RCT by Shearer and co-workers struggled with low interest in 
participation and the trial was discontinued when the group randomly allocated to oral 
naltrexone failed to initiate treatment. The other three trials unanimously conclude on the 
feasibility of oral naltrexone for inmates when integrated into psychosocial support that 
enhances external motivation, e.g. work-release programmes and parole including follow-up 
by criminal justice staff. Although treatment attrition was still high in these trials, those who 
stayed on oral naltrexone were less likely to relapse to heroin and less likely to engage in 
criminal activity. 
 
1.2. Opioid addiction 
Frequent use of heroin quickly leads to addiction, which can be characterised as an ongoing 
compulsive and pathological use pattern that the individual maintains despite the awareness of 
the health damaging consequences (Hasin et al. 2006). In substance addiction or drug 
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dependence, the motivational system and the neurotransmitter dopamine have been found to 
have primary importance (Koob & Le 2008). Behaviours that increase dopamine levels such 
as the use of psychoactive substances will be linked to wanting and liking. The incentive 
sensitization theory postulates that repeated stimulation with psychoactive substances will be 
followed by neuroadaptation that may lead to a decrease in liking and an increase in wanting 
(Robinson & Berridge 2008). These motivational changes are believed to be maintained by 
substance induced genetic re-arrangements of neuronal functioning in the brain’s mesolimbic 
system (Nestler 2008). This system and the limbic forebrain (e.g. prefrontal cortex) are 
described as the brain reward circuit and play an important role in motivation (Wise 2002). 
The brain reward circuit mediates the reinforcing effects of heroin through opioid receptors 
(OR) of dopaminergic neurons that are located in the nucleus accumbens (NAc) and ventral 
tegmental area (VTA) (Nestler 2001). In these neuroanatomical regions, heroin induces 
supraphysiological activation and thus constitutes a stimulus that is likely to become more 
salient than natural activating stimuli such as food intake, sex and child care (Volkow et al. 
2004).  
 
Immediate and long-term effects of heroin on neurons of the brain reward circuit are 
suggested. The immediate heroin effects consist of increased signalling of dopaminergic 
neurons in the VTA. This leads to increased dopamine release in the NAc and the prefrontal 
cortex which causes heroin-induced euphoria. The repeated exposure to heroin results in 
opioid receptor desensitization and down-regulation. In consequence, heroin tolerance is 
increased and dopamine release decreased unless larger amounts of heroin are taken. Long-
term heroin exposure will eventually lead to long-term neuronal adaptation, such as altered 
gene transcription patterns (e.g. CREB), altered post-transcriptional mechanisms (e.g. changes 
in protein degradation) and changes in the synaptic structure of dopaminergic neurons in the 
NAc. These effects of heroin and other drugs of abuse in the brain reward circuit are 
suggested to form the neurobiological basis of drug addiction (Leshner 1997; Volkow & Li 
2004).  
 
The opioid withdrawal syndrome occurs after discontinuation of opioid intake. The principal 
symptoms are irritability, anxiety, muscular and abdominal pains, chills, sweating, sneezing, 
rhinorrhea and insomnia. Withdrawal is suggested to be a rebound in adrenergic hyperactivity 
in the locus coeruleus where heroin induces reduced signalling. The pre-synaptic alpha-2 
noradrenergic agonists clonidine and lofexidine alleviate the opioid withdrawal syndrome 
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(Gossop 1988; Strang et al. 1999). However, withdrawal symptoms are more reliably 
alleviated by repeated opioid use and thus withdrawal plays a major part in maintaining 
frequent heroin use and addiction (Gold 1993).  
 
The strong reinforcing effects of heroin together with the unpleasant withdrawal syndrome 
support the understanding of the compulsive drug taking behaviour observed in opioid 
addicts. The more recent neurobiological findings have been integrated in an addiction 
medicine framework, in which drug addiction is regarded as a chronic relapsing disorder 
comparable to other chronic medical conditions such as non-insulin-dependent diabetes 
mellitus (NIDDM) and hypertension (O'Brien & McLellan 1996). In such chronic disorders, 
most medical treatment approaches will not be curative of the pathophysiology of the 
underlying disease. Nevertheless, medication can be an effective means to achieve important 
treatment goals such as symptom relief and substantial reduction of co-morbidity. The effects 
of medication are significantly enhanced by the individual’s motivation and ability to comply 
with other health promoting behaviours such as diet and training to reverse NIDDM, or 
reduced drug and alcohol use to significantly change an addicted lifestyle. 
 
1.3. Opioid maintenance treatment with methadone or buprenorphine 
Illicit opioids and mainly heroin remain the principal addictive drugs for which individuals 
seek treatment in the EU (EMCDDA 2008). The most widespread treatment approach is OMT 
with methadone or buprenorphine (Lobmaier et al. 2010). Methadone maintenance treatment 
was first described by Drs. Dole and Nyswander more than four decades ago (Dole & 
Nyswander 1965). This early medical approach is based on the biological principle of 
replacing the short acting heroin with the longer acting methadone. It also emphasizes that 
methadone is only the first, but maybe decisive step towards improving the social relations 
that had been impaired during several years of drug addiction (Dole & Nyswander 1980). 
 
Since the late 1990s, the partial µ-OR agonist buprenorphine has become available for opioid 
maintenance treatment. When compared to methadone, the main advantage of buprenorphine 
lies in its ceiling effect which makes respiratory depression and fatal overdoses less likely. A 
potential drawback is a slightly lower treatment retention rate. Other important outcomes such 
as heroin use, non-opioid drug use and criminality have been found to be of comparable 
effectiveness for methadone and buprenorphine (Mattick et al. 2008). 
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Methadone and buprenorphine have longer half lives than heroin and reach their peak plasma 
concentrations later. When doses are increased slowly their sedative effect is markedly 
reduced and during long-term use with adequate and stable doses opioid-induced euphoria is 
usually lacking. With appropriate daily doses of methadone (between 60 and 120 mg) or 
buprenorphine (between 8 and 24 mg; or doubled doses every other day), individuals 
dependent on illicit heroin will rarely experience withdrawal including drug craving (WHO 
2009). If heroin is used after the ingested dose, the desired euphoric effect is blocked. 
Therefore, during OMT the dependent individuals may be able to replace heroin seeking 
behaviour with other and more meaningful activities such as education or meeting friends and 
family. They may even be able to support themselves economically through regular work. 
Agonist maintenance treatment with methadone or buprenorphine facilitates behavioural 
changes and can help individuals to overcome their addicted lifestyles. However, both drugs 
are agonists at the µ-opioid receptors. Hence, they also have a rewarding effect, a black 
market value and if discontinued, their absence will lead to withdrawal including craving for 
opioids. Furthermore, the neuroadaptation caused by heroin use is unlikely to be reversed. 
Therefore, OMT cannot be considered curative of the physiological dependence on heroin. 
Notwithstanding these limitations, OMT has been shown to retain patients in treatment longer 
than in any other treatment modality. It is also effective in reducing heroin use, but in an 
extensive Cochrane meta-analysis no statistically significant advantages were found for 
criminal activity or mortality outcomes (Amato et al. 2005). In large longitudinal studies 
evaluating OMT however, significant reductions have been reported for heroin and poly-drug 
use, drug-related crime and mortality (Clausen et al. 2008; Gossop et al. 2003; Teesson et al. 
2006). 
 
1.4. Antagonist treatment with naltrexone 
Another pharmacotherapy for opioid addiction is the use of antagonists at the opioid 
receptors. Naltrexone is the most prominent example and has been developed with substantial 
support from the US National Institute on Drug Addiction (NIDA) in the 1970s (O'Brien et al. 
1975). Naltrexone binds to all three OR subtypes with the highest affinity for the µ-OR and 
lacks the rewarding effect of agonists (Gonzalez & Brogden 1988). Naltrexone competes with 
opioid agonists for receptor binding sites and due to its high affinity naltrexone effectively 
blocks agonist binding. It also displaces full agonists such as heroin and methadone from the 
receptors and may thus precipitate withdrawal. To avoid major withdrawal symptoms such as 
nausea, vomiting and psychosis, naltrexone treatment is either induced after accomplished 
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detoxification (four to seven days after last opioid intake) or during heavy sedation or general 
anaesthesia, which may be used to curtail withdrawal symptoms. Side effects of naltrexone 
treatment, such as nausea, muscle pain and headache are generally found to be transient and 
mild to moderate (Gonzalez & Brogden 1988). Although dysphoria during naltrexone 
treatment has been reported, the relationship is not well established (Miotto et al. 2002; Ritter 
2002). 
 
In literature reviews on oral naltrexone, randomised comparisons with OMT are scarce 
(Johansson et al. 2006; Minozzi et al. 2006). Only two trials are reported. An Iranian open-
label RCT comparing 50 mg methadone and 5 mg buprenorphine daily with 50 mg oral 
naltrexone daily found superior treatment retention rates for methadone (Ahmadi et al. 2003). 
A Malaysian double-blind RCT comparing buprenorphine, oral naltrexone and placebo 
recently showed the superiority of buprenorphine maintenance (Schottenfeld et al. 2008). Of 
the 126 heroin-dependent participants, the group that was maintained on buprenorphine spent 
more time in treatment and relapsed later to heroin use than the groups receiving oral 
naltrexone treatment or placebo. For these outcomes, oral naltrexone was found to be inferior 
to placebo. 
 
The main findings of about four decades of oral naltrexone research are the low patient 
interest in taking naltrexone and the high rates of early treatment dropout (Fram et al. 1989; 
Tucker et al. 2004). Pharmacologically however, naltrexone is an effective option to prevent 
relapse to opioid use, and may even have the potential to allow reversal of neuroadaptation. 
To improve patient compliance, NIDA proposed the development of sustained-release 
formulations already in the 1970s (Willette 1978). Investigations of early formulations 
showed significant adverse local tissue reactions and were discontinued (Chiang et al. 1985). 
Not before the late 1990s, several formulations have achieved approval for evaluation in 
clinical trials.  
 
The majority of research on sustained-release naltrexone is based on cases (Brewer 2002; 
Hulse et al. 2003; Hulse & O'Neill 2002), small samples (Comer et al. 2002; Sullivan et al. 
2006; Waal et al. 2003; Waal et al. 2006) or cohort studies without a planned-comparison 
group (Carreno et al. 2003; Foster et al. 2003; Gölz & Partecke 2000; Hulse et al. 2004a; 
Hulse et al. 2005). Although prone to bias, these results unanimously indicate that sustained-
release naltrexone is beneficial for selected groups. The two Norwegian pilot studies that 
18 
 
investigated naltrexone implants were conducted without a control group. In the first study, 
implants were purchased from the US based Wedgewood Pharmacy and ten volunteers 
received at least one and a maximum of four implants that released naltrexone on average 30 
to 80 days (Olsen et al. 2004). At ten months follow-up, six participants had not relapsed to 
heroin use, but two patients had experienced local site reactions and their implants were 
surgically removed (Waal et al. 2003). The second study investigated single (three months) 
and double (six months) naltrexone implants imported from GoMedical Inc., Perth, Western 
Australia. Eight of the 13 volunteers reported no heroin use at eleven months follow-up and 
only one patient developed a tissue reaction at the implant site that needed surgical revision 
(Waal et al. 2006).  
 
In a Spanish sample of 156 outpatients that consisted largely of heroin smokers living with a 
partner and having stable work, self-reported drug use was found to be reduced during the 
twelve months follow-up (Carreno et al. 2003). Patients received an average number of 2.3 
Wedgewood one-month implants before opting for oral naltrexone. Retention in treatment 
was reported to be high with 80% of patients still attending the private clinic at six months 
and 65% at twelve months. In a British study investigating the same implant, the results from 
101 patients indicate a low opioid relapse rate of 23% at twelve weeks follow-up (Foster et al. 
2003). All patients attending the private clinic started naltrexone implant treatment during 
rapid detoxification. After their first implant, all patients could choose to continue the 
treatment on implantable or oral naltrexone. As the costs of the procedure and the implants 
had to be paid by the patients, some were reported to choose the low-cost option oral 
naltrexone for economic reasons.  
 
Similarly positive findings are reported from a German study investigating a locally produced 
six-weeks implant (Gölz & Partecke 2000). Following detoxification, 69 patients received one 
or more implants and another 39 received oral naltrexone. Naltrexone compliance in the self-
selected groups was improved when the implant treatment was made available during the 
course of the study. Opioid relapse rates were pooled for both groups and reported to be 19% 
after one and 30% after three months. Twelve months after detoxification and naltrexone 
induction, 47% of the patients on implantable or oral naltrexone had relapsed. The follow-up 
period for both treated groups was on average 18 months (range 44) with shorter periods for 
the implant treatment that became available later on in the study. Based on months in follow-
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up, the implant group spent 60% of their time opioid abstinent and the oral naltrexone group 
40%.  
 
In Australia, a cohort of about 360 patients who had undergone ultra-rapid opioid 
detoxification (UROD) with subsequent naltrexone implant treatment during 2001-02 was 
retrospectively investigated using a database record-linkage design. Four research questions 
were investigated and naltrexone implant treatment was generally associated with favourable 
outcomes: Firstly, non-fatal opioid overdoses leading to emergency department presentations 
were reduced six and twelve months after implant treatment compared to the six months 
before treatment (Hulse et al. 2005). However, an increase in non-fatal overdoses caused by 
sedative drugs was reported for the period after implant treatment start. They occurred mainly 
during the ten days following naltrexone induction and should therefore be considered 
UROD-related rather than caused by the naltrexone implants. Secondly, the mortality rates 
during the three years following naltrexone implant treatment were found to be comparable 
with the mortality of an MMT cohort who had started treatment during 2001-02 (Tait et al. 
2008). However, as the results are not based on a prospective and controlled trial, the direct 
comparison between the two groups is limited and therefore the results need to be interpreted 
with caution. Thirdly, hospital admission rates for mental health problems were found to be 
reduced during the almost two years after naltrexone implant treatment in comparison to time 
before treatment (Ngo et al. 2007). The reduction in admission rates was not found for mood 
disorders. Also, the risk of mental health related hospital admissions and length of stay were 
unchanged when comparing before and after treatment. Fourthly, drug-related morbidity and 
hospital admissions following naltrexone implant treatment were compared to a cohort who 
had received MMT (Ngo et al. 2008a). Hospital presentations for non-fatal overdoses from 
opioids decreased in the naltrexone implant cohort but not in the methadone maintenance 
cohort. However, non-fatal overdose-related presentations from other drugs than opioids 
increased in both cohorts. Also, in the naltrexone implant cohort hospital presentations 
increased for conditions that were unrelated to overdose or to non-opioid drug use. 
 
Despite insufficient evidence, treatment with unregistered depot and implant formulations 
(often in private clinic settings) is available in several countries such as Australia, China, 
Egypt, England, Germany, Portugal and The Netherlands. The proponents of sustained-
release naltrexone strongly advocate its efficacy despite the lack of rigorously controlled 
clinical trials (Brewer 2008). Another important unanswered question in naltrexone research 
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concerns therapeutic blood levels. It is still unclear at which naltrexone level a clinically 
relevant amount of heroin is blocked and to what extent. Blood levels of 1 - 2 ng/ml are 
suggested to block the effects of 25 mg heroin (diacetylmorphine) on the basis of single case 
reports and human laboratory studies (Brewer 2002; Chiang et al. 1985; Comer et al. 2002; 
Navaratnam et al. 1994; Resnick et al. 1974). 
 
1.5. Ethical considerations when conducting treatment research in prison 
Scepticism and hesitation towards clinical research that involves drug-involved inmates may 
be justifiable, because coercing prisoners into clinical trials has an infamous history. In the 
US, opium had been prohibited through the Harrison Narcotic Act since 1914 and in the 
following decades many addicts were sent to prison. When in 1935 the “United States 
Narcotic Farm” opened its doors in Lexington, it was given a dual role as prison and as 
hospital (Campbell et al. 2008). The goal was to provide treatment and nothing less than 
complete rehabilitation of both the incarcerated and the volunteering addicts. Moreover, 
Lexington had a laboratory known as the Addiction Research Center, where medical and 
criminal justice staff pursued another ambitious goal: finding the permanent cure for 
addiction. The inmates were recruited to research that included seminal laboratory studies, 
such as the identification of opioid receptors, the first application of methadone in humans in 
1948, and of buprenorphine just before the Farm and the Research Center were shut down in 
1974. In the same year, NIDA had been created and the Farm’s Addiction Research Center 
became NIDAs intramural programme (Kosten & Gorelick 2002). NIDA supported the 
development of naltrexone and sustained-release formulations from the very beginning 
(Bradford et al. 1976). This work was a continuation of the results from the laboratories at the 
Narcotic Farm, where the first application of an supposed opioid antagonist (cyclazocine) in 
man was reported (Martin et al. 1966). In the mid 1970s, closing the Narcotic Farm had 
become necessary because coercive drug research with inmates was then considered unethical 
and thus had to be banned. However, the experience from four decades of drug research with 
incarcerated individuals has also helped to outline guidelines on the special ethical 
considerations that are granted inmates today to protect them from coercive research (OHRP 
2003). These guidelines for involvement of prisoners in research recommend investigating 
addiction treatment in prison populations, because substance use, abuse and addiction are 
overrepresented there. The main features of the guidelines are that: 
• First contact between inmate and researcher is established entirely voluntary, which 
usually implies info through prison staff (health care or correctional). 
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• Participation is voluntary and independent of the terms of the sentence, e.g. access to 
visitors, exercise and release on parole. 
• All inmate information collected by researchers is handled confidentially. 
 
Quasi-compulsory addiction treatment as alternative to a pending prison sentence is available 
in many European countries including Norway and in the US (Sletnes 2005; Stevens et al. 
2005). All the different national approaches emphasize the individuals’ possibility to choose 
between punishment and treatment. In general, clinical research aims at improving health care 
and voluntary participation is considered crucial (Rickham 1964). Offering improved health 
care through clinical research in criminal justice settings may have particular implications for 
voluntary participation, because the gap between health care that is provided in prisons 
compared to the community is widely acknowledged (Taxman et al. 2007). When 
implemented in criminal justice settings, clinical research to improve treatment particularly 
aims at narrowing the health care gap between prison and the community. Some argue that 
this effort should be taken further: The authorities may even have an obligation to provide 
better health care in prisons than in the community, because they have an extraordinary 
responsibility for the individuals that are incarcerated, i.e. forced into a high risk situation by 
the authorities (Lines 2006b). However, unless research had a very strong rationale or 
sufficient evidence for making health care provided in criminal justice settings more available 
or better than in the community, it would hardly meet support in the public opinion as it 
would be perceived as coercive. 
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2. Aims of this thesis 
Treatment with naltrexone implants has become available for use in research during the last 
decade. Previously, heroin involved offenders have been found to benefit from oral naltrexone 
treatment upon community re-entry. The effects of naltrexone implant treatment for opioid 
dependence have not been investigated in a prison population.  
 
The aims of this thesis are: 
 
a) To present a systematic review of the literature on sustained-release naltrexone and to 
assess its effectiveness for heroin dependence. 
 
b) To evaluate the feasibility and effectiveness of naltrexone implant treatment in a 
randomised comparison with methadone treatment among heroin addicted inmates 
after prison release. 
 
c) To assess opioid use during naltrexone implant treatment and to evaluate the opioid 
effects experienced. 
 
Both published (see appendix) and unpublished data are reported in the thesis.  
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3. Methods and findings 
3.1. Literature review (Paper I) 
Aims 
A systematic review of the literature was conducted to evaluate the effectiveness and safety of 
the available sustained-release naltrexone formulations. 
 
Methods 
Two search strategies were developed: The first search identified reports to assess 
effectiveness of sustained-release naltrexone for opioid dependence and was restricted to 
randomised-controlled trials. The second search identified any report of the use of sustained-
release naltrexone in humans to assess safety. All retrieved references eligible for inclusion 
were independently assessed by two authors regarding relevance and potential risk of bias. 
For RCTs, the methodological quality was assessed according to predefined measures in 
accordance with Cochrane standards. Outcome measures were predefined and data were 
extracted independently by two authors. Any disagreement was resolved by consensus, if 
necessary by discussion with a third author.  
 
Statistical analyses 
Meta-analyses were performed when appropriate for all predefined outcomes using review 
management software (RevMan 4.2.) available online. Relative risks (RR) with 95% 
confidence intervals (CI) were calculated for dichotomous outcomes. Statistical heterogeneity 
between studies was assessed with Chi squared tests which indicate a confidence interval and 
a p-value to measure the probability of heterogeneity. Low p-values indicate significant 
heterogeneity and thus a variation in effect estimates that should be considered beyond 
chance. Further, RevMan calculates I-squared statistics indicating grades of heterogeneity 
ranging from zero (none) to one (a lot). 
 
 
Results 
Seventy four primary reports were obtained in full text and assessed for eligibility. To assess 
safety, 17 reports were included in the review. Only 1 of 17 reports was included to assess the 
effectiveness of sustained-release naltrexone for opioid dependence.  
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Effectiveness 
In the one report by Comer and colleagues, 60 heroin addicted outpatients were randomly 
allocated to one of three treatment arms in a double-blinded fashion (Comer et al. 2006). The 
double depot naltrexone injection (384 mg) was found to be more effective than the single 
depot (192 mg) or the placebo injection. The group receiving the double naltrexone dose 
showed a trend towards better treatment retention and dropped out significantly later than the 
groups receiving the single dose or placebo. Further, the double dose group scored “needing 
heroin” on a visual analogue scale significantly lower compared to placebo. On average, 
plasma levels in the double dose group were maintained above 1 ng/ml throughout the eight 
weeks study period.  
 
Safety 
Seventeen reports were included and among them were six RCTs; only one of six investigated 
an opioid dependent population. Opioid dependent samples were investigated in nine of 
eleven non-randomised trials; implants were used in the majority of the trials and most lacked 
a control group or did not systematically report safety outcomes. This substantially limited the 
safety assessment of the implants. 
 
However, when considering the safety outcomes reported from naltrexone depot treatment for 
alcoholism, we found frequent, but mild to moderate and transient side effects such as nausea 
and headache. Safety outcomes related to injection site reactions of the depot compared to 
placebo injections were largely similar and gave little reason for concern, but we found a 
statistically significant disadvantage of the naltrexone depot compared to placebo for two of 
eight adverse event (AE) outcomes (see Figure 1). 
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Figure 1: Comparison of lower dose naltrexone depot and placebo injection in the 
treatment of alcoholism: Selected safety outcomes 
Naltrexone:
events/N 
Placebo: 
events/N 
RR (fixed)
95% CI 
Weight 
% 
RR (fixed) 
[95% CI] 
Study or 
outcome
100.00  1.19 [1.02, 1.38] 
Outcome 1: one or more injection site reaction 
Kranzler 2004  123/167 103/166 
Test for overall effect: Z = 2.25 (p = 0.02) 
Outcome 2: injection site related AEs, pooled 
Kranzler 1998  16/30  4/10 
Kranzler 2004  247/668 205/664 
Garbutt 2005  18/210  19/209 
Subtotal (95% CI) 281/908 228/883 
2.60  1.33 [0.58, 3.06] 
89.14  1.20 [1.03, 1.39] 
8.26  0.94 [0.51, 1.74] 
100.00  1.18 [1.02, 1.36] 
Test for heterogeneity: 
Chi² = 0.63, df = 2 (p = 0.73), I² = 0% 
Test for overall effect: Z = 2.24 (p = 0.02) 
 0.01  0.1  1  10  100 
Favours naltrexone depot Favours placebo injection
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3.2. Challenges in clinical research involving problematic drug users in criminal justice 
settings (Paper II) 
Aims 
The various challenges in the study were analysed and solutions to the problems suggested. 
 
Methods 
In the open-label trial inmates were randomly allocated to naltrexone implants or methadone 
treatment. Candidates for the trial were suggested by prison staff or health services and then 
offered an info visit. Trial information that included the research staff’s contact details was 
made available in written form in brochures and posters. Participation was requested 
voluntarily and all candidates, relevant treatment providers and prison staff were informed 
orally and through written informed consent that participation was entirely independent of 
terms of the sentence, i.e. access to media, visitors, training or exercise, transfer to other 
sections or prisons and parole conditions. Further, study participants were systematically 
informed that the Norwegian methadone programme regulations apply; i.e. methadone 
initiation is scheduled through home community social services and approved by central 
OMT authorities. Research staff could not guarantee treatment approval, however the 
importance of methadone initiation before prison release for the success of the trial was 
emphasized. During the screening process, the candidates’ statements on heroin use before 
imprisonment were logged in order to distinguish between non-eligible and non-interested 
inmates. Whenever possible, the inmates’ plans to cope with heroin abstinence at community 
re-entry were noted. The reasons for dropout from the methadone and naltrexone implant 
group were compared and possible differences in sample characteristics were analysed.  
 
Statistical analyses 
Continuous outcomes were compared using t-tests or rank methods if the assumption of 
normal distribution was violated. Binomial outcomes were compared using Chi squared 
statistics with Fisher’s Exact Test for small groups. Statistical significance was tested two-
tailed at the conventional level of p=0.05. 
 
Results 
During one and a half years of recruitment, only 46 of 111 eligible inmates signed informed 
consent. Two of the 46 withdrew consent after random treatment assignment and did not 
provide complete baseline data. The 65 eligible inmates who refused participation had usually 
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undergone forced detoxification upon imprisonment. Challenges were the low interest, the 
randomised study design and aftercare. These were related to criminal justice settings in 
general and more specifically to clinical addiction research which extends beyond prison 
release. 
 
Low interest and ambivalence 
In contrast to heroin addicts in the community, treatment motivation of heroin-involved 
inmates is influenced by prison setting specific factors such as forced detoxification and a 
changing juridical status. Usually upon incarceration, inmates on remand await their charges 
before they are court sentenced to a certain number of weeks, months or years in prison. The 
date of regular prison release is not set until the charges have been accepted; and only then the 
time to a possible parole application becomes predictable. These changes in juridical status 
during several months of incarceration are likely to affect the inmates’ motivation to engage 
in any treatment that stretches beyond release and includes aftercare, as offered in our study.  
 
After spending weeks or months of their sentence, the inmates reported satisfaction with their 
drug free state and were eager to maintain it after prison release, most frequently by relying 
on their own resources. Some intended to apply for residential treatment or OMT, however 
hardly any stated more than vague plans for community re-entry. 
 
Prison staff was supportive of the trial and granted prison access at any time. Information was 
also spread through word of mouth by prison social workers, health services and core 
prisoners. Nonetheless, prison walls constitute a significant barrier that does not facilitate 
contact between researchers from the outside and the inmates. More continuous contact 
appears crucial to properly inform the inmates, to best understand their own expectations and 
to appropriately meet their fluctuating motivation and ambivalence. However, regular 
meetings with eligible inmates could not be achieved for several reasons: Inmates could be 
moved to other sections in the same prison or even to other prisons without further notice. 
Thus, they became subject to different routines, i.e. the scheduled time to spend on exercise, 
in the court yard and for other activities. Further, arranging info meetings with groups of 
inmates from several different prison sections depends on significant support from criminal 
justice staff: security must be evaluated continuously, inmates must be accompanied by staff 
and the meetings should be scheduled without affecting other activities. 
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Treatment preferences and random allocation to treatment 
When introducing the trial to eligible inmates, random allocation to the two fixed 
interventions was extensively discussed. Frequently asked questions were “Why random 
allocation?”, “Why is buprenorphine no option?”, “When do I get the first methadone dose?” 
and “What happens if I am in an emergency situation and need pain relief or anaesthesia 
while I am on the naltrexone implant?” 
 
All 46 consenting inmates were asked which of the two fixed interventions they hoped for 
before random allocation. As expected the largest proportion (43%) stated methadone 
maintenance, while 35% hoped for the naltrexone implant and 22% stated no preferred 
intervention. Participants were likely to refuse treatment initiation if the random allocation 
failed to meet their expectations. Two inmates even withdrew consent. Among the 44 inmates 
with complete baseline data, there was no statistically significant difference between the 17 
dropouts and the 27 treatment starters on core characteristics such as age, total time spent in 
prison and heroin use before current incarceration. Interestingly, reasons for dropout in the 
two groups differed. In the naltrexone arm, all eight who did not start treatment were 
dissatisfied and refused the randomly allocated treatment. However, dissatisfaction with 
randomly allocated treatment was also reported in the methadone arm and five of eleven 
participants refused to start methadone treatment. The remaining six non-starters could not be 
granted the support needed for MMT by the social services in their home community (see 
Figure 2). 
 
Beyond the prison walls: preparing release and scheduling aftercare 
To prepare inmates for release with study treatment initiated and aftercare scheduled proved 
difficult and required substantial effort. Release dates were uncertain for virtually all 
participants, either due to new verdicts pending or in anticipation of parole approvals. Also, 
during the study recruitment period, the urgent need of prison capacity in Norway had 
resulted in shortening sentences during incarceration in order to meet the increased demand. 
Inmates, who had originally been sentenced to six months or more in prison, could get their 
sentence reduced by ten days; if originally sentenced to twelve or more months the reduction 
could be by 20 days. These post court-room reductions could result in earlier than expected 
release dates, and since they were not granted to all inmates, they also contributed to the 
uncertainty of the release dates in our study.  
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Dropout from methadone occurred quickly and frequently: two of eleven methadone starters 
experienced side-effects and discontinued before prison release; another four were no longer 
receiving methadone on average 41.5 days (sd 55.7, range 113) post release. Dropout 
occurred mostly due to difficulties in daily meeting for dose pick up. Daily meeting was not 
required in the naltrexone implant group. Re-incarcerations occurred similarly often in both 
treatment groups, and was not more frequent than among those who had never initiated the 
per-protocol treatment. 
 
3.3. Naltrexone implant treatment compared to methadone in pre-release inmates: 
findings from the prison study at six months follow-up (Paper III) 
Aims 
To investigate the feasibility and treatment effects of naltrexone implants and methadone on 
the use of heroin and other illicit drugs, and criminality after prison release. The hypotheses 
were that naltrexone implant treatment would reduce heroin use significantly more than 
methadone, and further that both groups would improve while in treatment in terms of 
reduced criminal activity and reduced non-opioid drug use compared to baseline. Finally, we 
hypothesized that symptoms of depression and anxiety would not increase in participants 
receiving naltrexone implant treatment compared to methadone and to baseline. 
 
Methods 
Design and sample 
The study used a randomised-controlled, open-label design. The target population comprised 
opioid dependent inmates awaiting prison release. Exclusion criteria were clinically 
significant liver impairment, currently untreated major depression or psychosis, and 
pregnancy. Inmates who volunteered and signed informed consent were randomly allocated to 
naltrexone implant treatment or methadone maintenance.  
 
Interventions 
Methadone treatment was provided according to standard Norwegian programme regulations: 
Community social services had to support and file the participants’ application, which then 
had to be approved by the regional OMT authorities before the first methadone dose could be 
received in prison. Based on the experience from two previous pilot studies, participants 
received implants containing approximately 2.2 g of naltrexone, which is released at 
therapeutic levels for five to six months (Waal et al. 2003; Waal et al. 2006). The site in the 
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subcutaneous tissue of the lower, lateral abdominal wall where the implants were surgically 
inserted was inspected upon stitch removal, usually one to two weeks after surgery. 
 
Assessments 
The main outcome measures were heroin and non-opioid drug use and criminal activity, 
which were assessed with the European version of the Addiction Severity Index (ASI) for the 
time preceding the current incarceration (Kokkevi & Hartgers 1995). The ASI assesses seven 
domains of interest, among others education and employment situation, substance use history 
and criminal activity. The interview is designed for research and clinical use and requires 
three days training. Levels of reliability and validity have been found to be satisfactory 
(McLellan et al. 1992; McLellan et al. 1985).  
 
Depression and anxiety during incarceration were self-reported on Beck’s Depression 
Inventory (BDI) and the Hopkins Symptom Check List (SCL-25). The BDI consists of 21 
items that are scored from zero to three resulting in a max score of 63 points. A cut off value 
of 21 points has been suggested to distinguish cases of severe depression from non-cases in 
the original publication (BECK et al. 1961). The BDI has been reported to have good 
psychometric properties in drug dependent patients (Schaefer et al. 1985). The SCL-25 
consists of ten items measuring anxiety and 15 items on depressive symptoms (Derogatis et 
al. 1974). All items are scored from one to four, summed up and then divided by 25. Cut off 
values that indicate clinical significant depressive symptoms are suggested to lie between 1.5 
and 1.8 (Nettelbladt et al. 1993; Sandanger et al. 1998; Winokur et al. 1984). The final score 
can be used for screening and indicates general psychiatric distress. Side effects possibly 
related to naltrexone, such as headache, nausea, vomiting, anxiety / restlessness and muscle 
pain, were rated on a questionnaire from zero (not at all) to three (a lot) for the preceding 
week. 
 
All assessments were repeated six months after prison release. Heroin use was then 
additionally assessed by timeline follow-back, TLFB (Sobell L.C. & Sobell M.B. 1992). This 
interviewing technique uses a calendar method to assess the number of days with drug use 
during a given period, e.g. six months. In illicit drug users, TLFB has been found to have 
good reliability and high concordance with objective measures of drug use (Fals-Stewart et al. 
2000). In case of re-incarceration during the follow-up period, drug use was assessed for the 
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time preceding the new prison sentence, whereas for criminal activity the baseline values 
were imputed. 
 
Hair samples were analysed with liquid chromatography tandem mass spectrometry at the 
Division of Forensic Toxicology and Drug Abuse at the Norwegian Institute of Public Health 
(Hegstad et al. 2008). 
 
Statistical analyses 
For the intention-to-treat (ITT) analyses missing data were replaced with baseline 
observations, regardless of whether treatment was initiated or not. Mixed within-between 
subjects analyses of variance (ANOVA) were performed on heroin and illicit non-opioid drug 
use and criminal activity. Kaplan-Meier survival analyses were performed on days to heroin 
relapse (Kaplan & Meier P. 1958); missing data was replaced on the assumption of heroin 
relapse on day one following prison release. Differences between the groups were assessed 
with the log-rank test. For the completer groups, outcomes were analysed with t-tests for 
normally distributed data. If the assumption of normality was violated rank methods were 
used, i.e. the Mann-Whitney U test for between groups comparisons and the Wilcoxon 
signed-rank test for pre-post, within group comparisons. For pre-post comparison of 
dichotomous outcomes in two groups the McNemar test was used. All statistical significance 
was tested two-tailed at the conventional level of p=0.05. 
 
Results 
Of the 46 individuals who volunteered for the trial, 27 initiated the randomly allocated 
treatment: 16 of 24 in the naltrexone group and 11 of 22 in the methadone group. Figure 2 
gives an overview on study enrolment, drop-out, treatment initiation and follow-up. Two of 
the 19 individuals who did not initiate study treatment withdrew consent. They were excluded 
from the analyses and not contacted for follow-up. An overview on characteristics of the final 
sample is given in Table 1. On these characteristics, there were no statistically significant 
differences between the groups. 
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Table 1: Baseline characteristics of study participants by randomly allocated group 
 Methadone, n=21 Naltrexone implant, n=23 
Age, mean years (sd) 35.4 (6.6) 34.9 (7.4) 
Female, n (%) 1 (4.8) 2 (8.7) 
Heroin debut age, mean years (sd) 23.3 (6.2) 23.4 (7.1) 
Regular poly drug users, n (%) 18 (85.7) 20 (87) 
Current sentence length, mean months (sd) 8.5 (5.7) 10.3 (5.0) 
Years in prison during lifetime, mean (sd) 5.0 (4.6) 4.7 (4.0) 
Homeless before sentence, n (%) 10 (47.6) 6 (26.1) 
Heroin use† (sd) 25.0 (9.2) 27.8 (5.0) 
Amphetamine use† (sd) 9.5 (11.9) 11.0 (12.9) 
Benzodiazepine use† (sd) 15.9 (12.5) 14.5 (11.7) 
Criminal activity† (sd) 20.3 (12.1) 18.5 (12.1) 
Note: † indicates mean number of days during last month before imprisonment.  
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Figure 2: Number of inmates screened, enrolled, dropped out, treated and followed up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 allocated to naltrexone implants 
111 eligible 65 not interested 
Per-protocol: 
5 completers 
10 not initiated 
6 discontinued 
Per-protocol: 
13 completers 
7 not initiated 
3 discontinued 
172 inmates 
screened 61 non-opioid users 
46 consented and randomly allocated 
22 allocated to methadone 
maintenance 
11 received 
first dose 
16 received 
implant 
4 dissatisfied 
with allocation 
6 involuntary 
dropouts 
7 dissatisfied 
with allocation 
8 followed up, 
3 dropouts 
5 followed up, 
5 dropouts 
 
7 dropouts 
13 followed up, 
3 dropouts 
1 dissatisfied & 
withdrew consent 
23 in ITT 
analyses 
 
1 dissatisfied & 
withdrew consent 
21 in ITT 
analyses 
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The intention-to-treat sample 
The ITT analyses were performed on the 44 participants who were randomly allocated. For 18 
of 44 participants, missing data at six months follow-up were replaced by baseline values 
assuming an unchanged situation, i.e. relapse to frequent drug use and criminal activity 
following prison release. Of these 18 participants, ten had been allocated to the naltrexone 
implant group and eight to the methadone group. Nine of the 44 participants had been re-
incarcerated during follow-up and were interviewed in prison. The analyses showed a 
statistically significant reduction in heroin and benzodiazepine use, and criminal activity at six 
months follow-up for both groups (Figure 3). Naltrexone implant treatment and MMT were 
found to be comparably effective on these drug use outcomes and criminal activity. No 
advantage of one treatment over the other was detected. 
 
Figure 3: Drug use and crime in the ITT sample at baseline (before imprisonment) and six 
months follow-up by group 
 
Note: Bars indicate mean days per month, whiskers are standard deviations.  
The * indicates a statistically significant reduction (i.e. effect of time) in the analyses of 
variance. There were no statistically significant differences between the two groups. 
 
The survival analysis performed on days to heroin relapse showed no difference between the 
treatment groups (see Figure 4). Relapse to frequent heroin use during the six months 
following release was evident in 13 of 21 participants in the methadone group and in 7 of 23 
in the naltrexone group. 
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Figure 4: Relapse to frequent heroin use following prison release, intention-to-treat sample 
 
Note: Missing data for four participants in each group were imputed on the assumption of 
relapse on the first day after prison release. There was no statistically significant difference 
between the two groups (Chi squared 3.56; p=0.059). The mean time to relapse in both groups 
was 95.0 days (95% CI 68.0, 122.0). 
 
The survival analysis was modified and then repeated twice: Firstly, when data was imputed 
assuming relapse on the second day after release, this less conservative approach showed a 
statistically significant risk reduction for heroin relapse in the naltrexone group compared to 
methadone (Chi squared 4.04; p=0.044). The naltrexone group relapsed on day 112.8 (mean; 
95% CI 80.8, 144.8) whereas the methadone group relapsed on day 68.5 (mean; 95% CI 32.9, 
104.2). Secondly, when analysing the convenience sample (i.e. omitting the eight individuals 
who had missing data on heroin relapse) a statistically significant advantage of naltrexone on 
heroin relapse rates (Chi squared 4.33; p=0.038) was found. In this scenario, the naltrexone 
group relapsed on day 136.1 (mean; 95% CI 106.7, 165.5) whereas the methadone group 
relapsed on day 84.2 (mean; 95% CI 43.6, 124.8).  
 
The completer sample  
The treatment per-protocol sample comprised 13 participants in the naltrexone and five in the 
methadone group (see Figure 2). All 18 individuals still received the study medications when 
meeting for follow-up. A statistically significant reduction in use of heroin and non-prescribed 
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benzodiazepines was found in both groups compared to baseline (Table 2 and Figure 5). The 
reduction in criminal activity was borderline significant. The methadone group reported 
greater reductions in amphetamine use than the naltrexone implant group. Seven completers 
were re-incarcerated on average 94 days (sd 71.3) into the follow-up period, 5 of 13 in the 
naltrexone and 2 of 5 in the methadone group. The re-incarceration rates between the 
completer groups did not differ. 
 
Table 2: Drug use and crime in the completer sample at baseline (before imprisonment) and 6 
months follow-up 
 Naltrexone group, n=13 Methadone group, n=5 Within  
groups,  
p-values 
Between 
groups,  
p-values 
baseline at  
follow-up 
baseline at  
follow-up 
Heroin 26.5 (6.3) 4.9 (11.2) 26.0 (6.5) 4.8 (8.6) <0.001 0.474 
Illicit Benzo 14.0 (14.3) 9.4 (12.6) 18.8 (12.5) 4.0 (5.5) 0.031 0.526 
Amphetamines 12.1 (14.1) 11.2 (11.0) 6.0 (13.4) 1.0 (2.2) 0.659 0.021 
Criminality 18.9 (13.7) 12.5 (13.5) 24.0 (8.2) 11.4 (12.4) 0.055 0.934 
Note: Values indicate mean days per month with standard deviation in brackets. Rank-method 
statistics were used, i.e. the Mann-Whitney U test for comparisons between the two groups 
and the Wilcoxon signed-rank test for comparisons within both groups. Criminality data was 
imputed for re-incarcerated individuals. 
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Figure 5: Drug use and crime in the completer sample at baseline and follow-up by group. 
 
Note: Bars indicate mean days per month, whiskers are standard deviations. The * indicates a 
statistically significant reduction in both groups. Reduction in amphetamine use was greater in 
the methadone than in the naltrexone group. No between groups differences on the other 
outcomes were found. 
 
Depression and anxiety were self-reported on the BDI and Hopkins SCL-25 during 
incarceration and again six months after release. Only data from completers were analysed 
and no differences were found. The naltrexone group scored on average 11.9 on the BDI 
before treatment start and 12.3 after six months. The methadone group scored on average 16.2 
before treatment start and 12.8 after six months. With the BDI cut-off value of 21 or more 
points indicating depression, 2 of 13 participants in the naltrexone group were defined as 
cases at follow-up compared to 1 of 5 MMT participants. There was no change from baseline. 
On the Hopkins SCL-25, the naltrexone group scored on average 1.45 at baseline and 1.86 at 
follow-up. The MMT group scored on average 1.84 at baseline and 1.75 at follow-up. With 
the cut-off score of 1.75 or more indicating clinical significant depression / anxiety, 6 of 13 
participants were defined as cases in the naltrexone group at follow-up, compared to 1 of 4 in 
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the MMT group. In the naltrexone group at follow-up, the number of cases had not increased 
significantly compared to the 3 of 12 cases found at baseline (McNemar test p=0.375). 
 
Hair analyses were available for 18 of the 44 participants. When compared to the results from 
self-reported heroin use, 13 of the 18 pairs (72%) were concordant. Of the five pairs that were 
not concordant, one participant in the MMT group reported relapse, but the heroin metabolite 
6-MAM was not detected in hair. The remaining four participants did not report relapse, but 
6-MAM was detected in their hair samples. Three were receiving naltrexone treatment and 
one MMT. 
 
Adverse events and side effects in the naltrexone implant group 
During the six months follow-up period, none of the 16 naltrexone implants was surgically 
removed due to site reactions. One participant requested the removal due to nausea 
approximately five months into follow-up. He had then relapsed to infrequently injecting 
heroin and had repeatedly failed to meet for appointments, making implant removal not 
feasible. Another two participants reported itching and skin rash at the implantation site, 
which resolved with oral antihistamines on the one and oral antibiotics on the other occasion.  
At 9 and respectively 14 months after treatment start, two participants had implant remains 
removed on their own request, citing cosmetic reasons. Infrequently reported symptoms such 
as headache and nausea were considered side effects that were possibly related to naltrexone, 
but not to the implant-site or surgical procedure.  
 
On average 12 days (sd 6.1) after treatment start, only 8 of 16 participants had completed the 
self-report side effects questionnaire. The highest average score on the 0 to 3 scale was rated 
for headache (0.88) followed by trouble sleeping (0.75), reduced appetite (0.75), irritability 
(0.57) and nausea (0.50). During the first month in treatment, none of the participants rated 
the symptoms as 3, worrying them “a lot”. Missing data on side effects limits the analyses of 
the development over time. However, the narratives of the majority of participants who met 
for follow-up supported the questionnaire data. Participants did usually not relate the reported 
symptoms specifically to the naltrexone implant and experienced those side effects reported 
as little troublesome. 
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3.4. Opioid use despite naltrexone blockade: Effective overriding? [Paper IV] 
Aims 
To investigate the possible overriding of the blockade provided by naltrexone implants with 
opioids. It was expected that participants would test the blockade only a limited number of 
times and that hardly any participant would use opioids frequently. 
 
Methods 
Any opioid use by participants receiving naltrexone implant treatment was assessed, and 
whether or not they reported experiencing a euphoric effect (i.e. got high). Data from the 
prison study were pooled with data from two outpatient studies. A total of 60 participants who 
had received a naltrexone implant for the first time were included in the analyses. Fourteen of 
the 60 were women, 42 were discharged from inpatient treatment settings and 18 came from 
the prison study.  
 
The outpatient studies 
The aim of these two studies was to evaluate the effects of naltrexone implant treatment in 
outpatients recently discharged from long term residential treatment or short term hospital-
based detoxification. Participants were recruited from inpatient units in south-eastern Norway. 
In both the pilot and the randomised-controlled outpatient study, the control condition 
consisted of regular aftercare following discharge such as counselling, medication with oral 
naltrexone, OMT, or other treatment modalities. Participants in both groups were free to 
choose their treatment from the existing alternatives in their home community and in 
cooperation with local social services. Naltrexone implants were given as a supplement to 
usual aftercare. Naltrexone implant treatment was initiated before discharge. In both studies, 
the structured interview Addiction Severity Index was the principal tool to assess drug use. 
Hair samples were taken in the RCT only. Both studies were approved by the South 
Norwegian Regional Committee for Medical Research Ethics and the Norwegian Social 
Science Data Services. The studies were funded by the Southern Norway Regional Health 
Authority and registered publicly at http://clinicaltrials.gov, identifier NCT00269607 (pilot) 
and identifier NCT00521157 (RCT). 
 
The first, unpublished study was a non-randomised pilot using a matched-controlled design 
with patients volunteering for implant treatment and a comparison group, who was matched 
on key variables such as age, gender and onset of opioid dependence. As enrolment was going 
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slow, the study was discontinued when twelve participants were included. Six had initiated 
naltrexone implant treatment and all six are included in this data analyses. In the second 
study, 56 patients were enrolled and randomly allocated to one of two groups. The outcomes 
for the naltrexone implant group were advantageous at six months follow-up (Kunoe et al. 
2009). Group crossover was optional at six months follow-up, resulting in 36 participants 
eligible for the current analyses. All of them had started naltrexone implant treatment for the 
first time during the total of twelve months follow-up.  
 
Measurements and definitions of opioid use and effect 
In all three studies included in the current analyses, self-reported use of heroin, 
buprenorphine, methadone and prescription opioids was analysed separately and then 
combined in an ‘all opioids’ category. Opioid use was categorised as ‘high frequency’ in case 
of five or more days of use during follow-up and as ‘low frequency’ in case of four or less 
days of use, allowing comparisons of two groups of users. Special attention was given to 
buprenorphine during data collection and analyses as buprenorphine has relatively high µ-OR 
affinity and was therefore regarded as the opioid with the greatest potential to override the 
naltrexone blockade. In accordance with this assumption, buprenorphine was pointed out as a 
possible pain reliever in case of a medical emergency on an implant carrier's card, which was 
provided for all participants. Outcome variables such as use of non-opioid drugs, health 
status, social functioning, and crime were also assessed.  
 
During the follow-up interview, the participants were asked to describe their experienced 
opioid-related euphoria or ‘high’. Patients were also asked about opioid tolerance and 
withdrawal symptoms according to DSM-IV diagnostic criteria. Reported statements were 
then rated independently by two researchers on a scale from zero ‘no high’ to three ‘full high’, 
with one indicating ‘uncertain high’ and two ‘some high’. In case of disagreement, the higher 
rating was chosen. For every participant who reported opioid-related euphoria, information on 
opioid type and dosage, and extra hair- and blood samples were requested. Naltrexone blood 
levels were plotted against the implant’s release profile described earlier (Hulse et al. 2004b; 
Ngo et al. 2008b). For ethical reasons, an agonist challenge paradigm to directly assess the 
extent of blockade override was not conducted.  
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Statistical analyses 
Analyses of variance (ANOVA) controlling for gender and age were performed post-hoc for 
within group (i.e. opioid use over time) and between groups comparisons (i.e. high vs. low 
frequency use). If the assumption of normal distribution was violated rank methods (e.g. 
Spearman’s rho) were used instead. Chi squared statistics were used for binomial outcomes, 
with Fisher’s Exact Test for small groups. All statistical significance was tested two-tailed at 
the conventional level of p=0.05. 
 
Results 
The full sample of 60 participants had a mean age of 33.7 (sd 8) years. Mean duration of 
heroin use was 6.7 (sd 4.5) years, poly-drug use was 10.4 (sd 7.4) years and injecting drug use 
was 9 (sd 8) years. Mean time spent in prison was reported to be 3.8 (sd 6.3) years and years 
of completed education were 11 (sd 2). Five participants did not attend follow-up and their 
data were collected by telephone interview with them or with significant others. No fatal drug 
overdoses were reported in the cohort and no individual had opioid withdrawal or increased 
tolerance that would indicate current dependence. Sixty blood samples were taken throughout 
the 180 days follow-up period and in 95% of samples the naltrexone and 6-beta naltrexol 
levels were found to be above 1 ng/ml. 
 
Opioid use pattern, effect and factors associated with override 
Testing the naltrexone blockade with opioids was reported by 34 (57%) individuals: 19 had 
mostly used heroin, nine buprenorphine, five morphine tablets and one methadone. The 
individuals who had used mostly buprenorphine to test the blockade reported more pre-
naltrexone experience with illicit buprenorphine and with OMT than the non-using 
individuals. The opioid users were more likely than the non-users to also use cannabis, 
amphetamines and illicit benzodiazepines during the study period. They also injected drugs 
more often and committed more acquisitive crime than the non-users. 
 
Sixteen reported high frequency use and at follow-up this group had returned to levels of use 
comparable to those reported before treatment start. Five injected mainly buprenorphine. The 
18 participants who reported low frequency opioid use typically tested the naltrexone 
blockade at the beginning and again at the end of the implant period. At follow-up they 
reported an opioid use reduction.  
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Of all 34 participants who had used opioids, nine reported feeling ‘some’ or ‘full high’. One 
non-fatal overdose was reported. Nineteen users did not feel any effect while three were 
uncertain about the effect. The remaining three users did not make a statement. The nine users 
who reported override of the naltrexone blockade differed from the 22 users who did not 
achieve an opioid effect. During the study period, the override group had used more illicit 
benzodiazepines and more opioids, particularly buprenorphine. 
 
4. Discussion 
4.1. Findings and limitations 
4.1.1. Literature review [paper I] 
The one study on depot naltrexone showed a dose dependent benefit in terms of reduced 
heroin use and increased treatment retention. The methodological quality was considered 
good with low risk of methodological bias. The primary outcome measures that allowed 
calculation of effect estimates were treatment retention (number of participants) and time to 
drop out (days in treatment). Opioid positive urine samples were reported on a group level in 
the original article, but the number of samples per participant was not available. Group based 
urine samples are likely to be biased towards individuals that were compliant with urinalyses. 
This issue was addressed in the original article by imputing missing data on the assumption of 
positive urine samples. However, this procedure may overestimate heroin use. For the 
Cochrane review, calculation of an effect measure from urinalysis was not recommended by 
the CDAG and thus not performed. According to Cochrane standards, a single RCT is 
considered insufficient evidence to conclude on treatment effectiveness. 
 
For naltrexone implants, two randomised-controlled trials on the Australian naltrexone 
implant have recently been reported (Hulse 2009; Kunoe et al. 2009). Both trials support the 
effectiveness of this implant to reduce heroin use, compared to treatment as usual in the 
Norwegian setting and compared to oral naltrexone or placebo in the Australian setting. These 
studies will be included in an update of the systematic literature review. 
 
The strength and also the major limitation of systematic Cochrane reviews lie in the exclusion 
of non-randomised studies (Cochrane Handbook 2008). For example, in systematic reviews of 
pharmacotherapies that are frequently investigated in RCTs such as antipsychotics, this 
restriction may be highly relevant in order to assess the specific effect of the medication in a 
direct comparison with strong internal validity and a very low risk of bias. A meta-analysis of 
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150 double-blind RCTs with more than 21000 patients investigated the claimed advantage of 
newer antipsychotic drugs compared to older drugs such as haloperidol (Leucht et al. 2009). 
In this systematic review, the newer antipsychotics were not found to be better than the first-
generation drugs, although open-label studies have systematically reported their advantages. 
Such studies were, however, excluded from the meta-analyses according to the standards of 
the Cochrane collaboration. When these strict methodological standards are applied to review 
an unconventional treatment, the evidence from RCTs is likely to be scarce; in the case of 
sustained-release naltrexone, only one RCT could be included to assess effectiveness. 
Furthermore, in the experimental design of randomised trials, strict patient inclusion and 
exclusion criteria are usually applied. This procedure in itself will introduce bias, because it is 
likely to attract a study population that differs from the average patients attending drug 
treatment services. An example from alcoholism research is reported, in which a single 
exclusion criterion (from a list with common criteria) was sufficient to exclude half of the 
1484 alcohol dependent patients that had been identified in a representative US population 
sample (Blanco et al. 2008). Studies with high internal validity such as RCTs may have a low 
risk of bias, but they are also likely to have rather poor external validity which limits the 
generalizability of the findings to average community populations.  
 
When systematically reviewing sustained-release naltrexone treatment, our suggestion to open 
study inclusion criteria for non-RCTs in the assessment of effectiveness was rejected by the 
Cochrane Drugs and Alcohol group. Hence, we were not allowed to consider all the available 
evidence in our review. On the other hand, the non-randomised trials on sustained-release 
naltrexone for opioid dependence that we excluded were usually prone to bias. Reports from 
small samples in single-group pilot studies do not allow direct comparisons (Hulse & Tait 
2003; Waal et al. 2003; Waal et al. 2006). Even larger studies with groups of 50 or more 
patients lacked properly controlled conditions and thus effectiveness assessment could not be 
performed (Gölz & Partecke 2000). In two trials with comparison groups, the enrolment 
procedure was prone to selection bias, because patients were recruited from private clinics, 
where they chose and paid for the experimental treatment: rapid detoxification with 
subsequent naltrexone implant treatment (Colquhoun et al. 2005; Foster et al. 2003). In 
another trial, patient follow-up was conducted by telephone interview only and dropout was 
not accounted for in the analyses resulting in a high risk of attrition bias (Carreno et al. 2003). 
Importantly, the drawbacks of the above described non-randomised trials would not be 
resolved by a random allocation procedure alone. Both attrition and detection bias can be 
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accounted for in well-conducted longitudinal studies by complete reporting of drop outs, 
performing intention-to-treat analyses and if possible, blinding the outcome assessors for the 
treatment modality.  
 
As sustained-release formulations require a minimally invasive procedure, we intended to 
specifically assess the safety of such naltrexone formulations in the systematic literature 
review. For the safety assessment non-randomised studies were accepted by the Cochrane 
Drugs and Alcohol group. The main results indicated transient, mild to moderate side effects 
related to the drug naltrexone. Depot formulations appeared to cause more injection site 
related side effects than the placebo injections. In line with these findings, the FDA issued a 
warning in December 2008 for the naltrexone depot Vivitrol® after several reports of injection 
site reactions. 
 
4.1.2. The prison study   
Challenges during trial implementation [Paper II] 
Interest in participation among eligible inmates was low, despite ample information and a low 
threshold for face-to-face information meetings. Offering regular group meetings during 
incarceration could have improved interest. However, frequent meetings will rely on research 
staff who spends substantially more time in the prison and who is integrated to a large extent 
in the prisons’ daily routines. On the other hand, such engagement from research staff may 
threaten their independent role.  
 
Random allocation to methadone and naltrexone is a challenging task due to their distinct 
pharmacology. A direct comparison had hardly been attempted with one example reported 
from an Iranian outpatient setting (Ahmadi et al. 2003). Randomly allocating prison inmates 
was earlier found to be particularly challenging, because the play of chance that 
randomisation implies had been perceived as extremely unfair and was therefore rejected 
(Erez 1985). Methadone maintenance treatment is still controversial and not optimally 
implemented in criminal justice settings. Inmates in the experimental group received 
naltrexone implants which unlike methadone lack a rewarding effect. Thus naltrexone is 
likely to be considered the most favourable pharmacotherapy by criminal justice staff, in 
contrast to the inmates receiving treatment. In line with findings for heroin addicts in the 
community, we expected the inmates to prefer methadone to naltrexone.  
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Aftercare preparation and follow-up were impeded by the need to coordinate researchers with 
criminal justice staff, prison health services and community treatment providers. For trial 
participation, the time frame of two months time to release was chosen as inclusion criteria. 
The objective was to be able to prepare treatment initiation and multidisciplinary group 
meetings. This time frame proved too short, especially for the methadone group which needed 
more extensive preparation before receiving the first dose. 
 
The scarce evidence on the effectiveness of addiction treatment programmes in criminal 
justice settings may be due to particular barriers encountered there, e.g. scepticism towards 
pharmacological strategies to treat addiction in general and maintenance treatment with 
agonists that have abuse potential in particular (McMillan & Lapham 2005; Zamani et al. 
2009). Another barrier may lie in the limited acknowledgement of addiction as a chronic brain 
disease in the general population, which is also evident in health care services and the 
criminal justice system. The definition of addiction as a disease implies the need for a 
criminal justice health care approach that goes far beyond forced detoxification upon 
imprisonment and a zero tolerance policy in case of relapse. Therefore, efforts to implement 
clinical addiction research in criminal justice settings, where usually punishment is exerted as 
the principal promoter of changing deviant behaviour, may be less likely to succeed compared 
to addiction specialist services.  
 
Dropout before and after treatment start occurred frequently and indicates that a self-selected 
sample was recruited. On the one hand, random allocation to the fixed interventions 
contributed to the high attrition rates. Treatment preference appeared to be an important 
selection factor in our sample, although there were no differences on socio-demographic or 
drug use characteristics, neither between naltrexone and methadone groups nor between 
treatment starters and dropouts. On the other hand, methadone as a control condition was 
attractive and contributed therefore to inmates accepting the experimental condition to a 
larger extent. Despite initial scepticism quite a few participants changed their mind and 
started naltrexone treatment. Offering methadone in our RCT may in fact have contributed 
significantly to the rather large proportion in the naltrexone group accepting the experimental 
treatment. However, it cannot be ruled out that random allocation to the fixed interventions 
has resulted in selective attrition and thus it may have failed to limit selection bias in our 
small sample. To reduce the risk of selective attrition, we could have allocated the control 
group to oral naltrexone instead of methadone. A direct comparison of naltrexone tablets with 
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implants in a double-blind, double-dummy randomised trial has now been reported in an 
outpatient community setting in Australia (Hulse et al. 2009). This design appears as the 
reasonable first choice also for criminal justice settings. However, we opted against it for two 
reasons: the low patient interest in naltrexone treatment is well known and offering only 
naltrexone would have made the trial virtually impossible to complete during the funding 
period of three years. Further, the effectiveness of methadone in community settings is well 
established and there is every reason to assume that it produces comparably good results in 
criminal justice settings. OMT in general must be made easier available to more inmates and 
we assumed that our trial with methadone as a control condition would contribute to 
improvement.  
 
Finally, more advanced strategies such as sequential, multiple random assignments (SMART) 
could have been attempted in order to meet participants’ preferences to a larger extent. 
Supposedly, more inmates would have performed better throughout the follow-up if we had 
succeeded to better match the treatment with their preferences. Adaptive treatment strategies 
have been suggested to be useful for the investigation of chronic disorders such as drug 
addiction (Murphy et al. 2007). They allow for re-routing participants to receive the most 
appropriate treatment, which is adjusted throughout the study course according to pre-defined 
variables such as responsiveness or preference and motivation. An important limitation of 
SMART strategies is that two-group, fixed intervention trials are still needed for the 
confirmation of findings. Additionally, multiple randomisation will by definition result in 
allocating to more than two groups, which implies the need for testing of multiple hypotheses 
and thus larger samples (Bauer 2008). 
 
Outcomes at six months after prison release [Paper III] 
Both treatment groups showed reductions in the use of heroin and illicit benzodiazepines and 
in criminal activity after prison release, at six months follow-up. For these outcomes, and for 
time to heroin relapse, patients allocated to naltrexone implants and methadone treatment 
showed similar levels of reductions in problem scores, and in these respects the two 
treatments may be regarded as being of comparable effectiveness. 
 
The two study groups showed different treatment performance. In the naltrexone implant 
group treatment retention was higher than in the methadone group, but naltrexone acceptance 
was lower. Some methadone group participants also refused to initiate treatment due to non-
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acceptance, but the main contributing factors to unsatisfactory methadone initiation were the 
programme’s application process that relied on community treatment providers and the 
complicating prison routines. Retention in the methadone treatment programme was low. This 
may have been due to the requirement of daily dose pickup which proved difficult to comply 
with for many individuals. The differences in treatment retention at six months may be partly 
attributed to the very different formulations of the two medications. All participants who 
started treatment in the naltrexone implant group were receiving this treatment six months 
after prison release: none had the implant surgically removed. For participants who started 
methadone treatment, the majority were not receiving medication at six months after release.   
 
Only two of our initial hypotheses predicted our findings. We expected reduced drug use and 
reduced criminal behaviour in both treatment groups compared to baseline. We were not able 
to conclude on the other hypotheses, as our study sample was small and attrition high. For 
heroin use reduction, there was no statistically significant advantage of naltrexone over 
methadone. This finding was influenced by missing data at follow-up, which were imputed on 
the assumption of a worst case scenario. Also, we failed to contribute to the question of 
whether or not naltrexone can cause depression because dropout after treatment start was 
high. In a study published a few years ago, no association between depression and naltrexone 
effects was found; on the contrary, depressive mood improved among those who were 
compliant with oral naltrexone (Dean et al. 2006).  
 
Hair analyses were available for 41% of the ITT sample and supported the self-reported drug 
use outcomes to a large extent. However, hair analyses as an objective method of drug testing 
is not yet established and results are vulnerable to pre-analytical handling of the samples. The 
extent of drug use that results in reliable and sensitive findings in hair needs further 
investigation. Although separate analyses of hair segments that are suggested to correspond to 
one month were planned, this approach appeared not feasible. Therefore, findings from the 
hair analyses were not published together with the self-reported drug use outcomes.  
  
Relying only on self-reported drug use data for the time prior to prison may have resulted in 
recall bias. More importantly, it may have given inmates the possibility to claim opioid 
addiction in order to receive methadone although they may not have used opioids regularly. 
Methadone diversion is a known problem in the community and its black market value is 
supposedly even higher in prison. Opioid addiction was diagnosed retrospectively for the time 
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before the current incarceration, because proper assessment would have needed substantially 
more manpower. Prison health services usually have limited resources and although screening 
all inmates for eligibility upon imprisonment was planned, it proved not feasible. 
 
4.1.3. Overriding the naltrexone blockade by injecting opioids? [Paper IV] 
Opioid dependent patients who received sustained-release naltrexone implants showed a mean 
reduction in opioid use during treatment. This reduction was unevenly distributed. Almost 
half of the naltrexone patients did not use opioids at all. However, more than half of the 
sample challenged the antagonist effects of naltrexone at some point during the six month 
treatment period. More interestingly, about a quarter of the sample challenged the blockade 
repeatedly, and 15% reported having used opioids on at least 90 days during the 180 day 
study period.  
 
This repeated use of opioids despite receiving naltrexone is difficult to understand. The 
majority of opioid use took place when naltrexone levels were above the therapeutic limit of 
1-2 ng/ml of naltrexone. This suggests factors other than naltrexone concentrations were 
important to opioid use.  
 
The override phenomenon has earlier been reported for single cases in oral naltrexone 
treatment which is subject to considerable uncertainty regarding medication compliance 
(Brewer 2002; Haas et al. 1976). Recently, two case-reports of override during sustained-
release naltrexone treatment were published. A patient treated with the Russian two months 
implant Prodetoxon® experienced a non-fatal overdose after having injected very large 
amounts of heroin (Kruptisky et al. 2007). Another patient used nasal oxycodone with effect 
during treatment with the injectable Vivitrol (Fishman 2008). Although our sample of 
naltrexone implanted patients is larger, the results are far from conclusive. Our data were 
collected after drug use had taken place and we did not have the opportunity to observe 
objective opioid effect measures such as pupil diameter or vigilance. Our findings need 
further investigation, because despite the pharmacological blockade that naltrexone provides, 
opioid injection and even overdoses may occur among implanted addicts. Although the 
majority is unlikely to use opioids frequently or to experience an effect, some patients will 
relapse and of these, some will report an effect.  
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Possible explanations for override may lie in pharmacogenetic aspects of naltrexone (Haile et 
al. 2008; Mitchell et al. 2007) or in gender differences that might affect treatment response 
(Suh et al. 2008). It must also be kept in mind that the participants in our studies received 
implants pending the validation for human use. Therefore, variation in production standards 
and naltrexone release rates might have occurred and allowed opioid effects in some 
individuals but not in others. Since claimed override has occurred across the various batches 
of implants that were imported from Australia, and since the majority of blood analyses 
showed naltrexone levels above 1 ng/ml, these concerns appear unfounded. However, blood 
naltrexone levels should be monitored frequently also in future studies investigating 
formulations not validated for human use. 
 
Another limitation of our data lies in the fact that it is unknown if the experienced effects in 
our sample were actually caused by the injected opioids. In our population, the reported 
effects were usually smaller than anticipated and they may have been triggered by a mix of 
memories, expectations and frequent injecting of benzodiazepines. The role of the high-
affinity partial agonist buprenorphine is still unclear; our data indicate that it may have been 
more effective for overriding than illicit heroin. However, for a more thorough investigation a 
human laboratory setting is needed that allows recording of objective agonist effect measures 
and application of intravenous drugs.  
 
4.2. Our findings in the light of other research 
Substitution treatment in prison has recently been reviewed and the authors conclude that 
methadone maintenance provided during incarceration reduces heroin and syringe use, 
improves health and supports social stabilisation (Stallwitz & Stover 2007). In a French 
observational study, about 80% of the investigated opioid-involved offenders were receiving 
OMT upon prison entry (Marzo et al. 2009). The study design limits the interpretation of 
effect measures. However, maintenance treatment with methadone or buprenorphine did not 
appear to have a beneficial impact on the re-incarceration rates during the three years follow-
up. In Australia, Dolan and colleagues have conducted a randomised-controlled trial on 
methadone maintenance during four months of continuous incarceration (Dolan et al. 2003). 
They found a significant reduction of heroin injecting among methadone maintained inmates 
compared to waiting list controls. All 382 participants were contacted again for another 
follow-up four years after (Dolan et al. 2005). Although re-incarceration rates and drop-out 
from the initial methadone treatment were high in this cohort, longer periods with MMT were 
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associated with improved outcomes on mortality and criminal activity. Improved outcomes 
during methadone and buprenorphine maintenance in the New York City jail system have 
been reported recently (Magura et al. 2009). In this randomised trial, inmates started OMT 
before release. Independent of treatment condition, they were likely to meet for the three 
months follow-up in the community and to report reduced heroin use. Buprenorphine 
appeared more acceptable than methadone in terms of higher intention to continue treatment 
also after release and more favourable drug-related outcomes. 
 
For pharmacotherapies other than methadone, conclusions for criminal justice populations 
cannot yet be drawn due to scarce evidence. A systematic Cochrane review on criminal justice 
system-based substance abuse treatment identified only one RCT on a pharmacological 
intervention for heroin dependence (Perry et al. 2006). In the report, oral naltrexone plus 
counselling was compared with counselling only among 51 parolees in an open-label RCT 
(Cornish et al. 1997). Participants in both treatment groups met biweekly for counselling with 
their parole officer. During the follow-up after prison release, the oral naltrexone group 
showed significantly less heroin use and re-arrests compared to the counselling only group. 
However, treatment retention rates at six months follow-up were comparable in both groups. 
Around 30% of the participants dropped out of treatment during the first study month with no 
differences between groups. In the Australian prison system, an open-label RCT on oral 
naltrexone compared to agonist replacement therapy was conducted (Shearer et al. 2007). 
Only 9 of 68 eligible inmates in the oral naltrexone arm initiated treatment. Random 
allocation failed because of low interest and the trial was discontinued.  
 
Since few RCTs on pharmacological treatment for heroin addiction during transition from 
prison to community aftercare have been conducted, the reduction in heroin use that we found 
together with the challenges that we identified and described are important contributions. For 
the large-scale RCT that was conducted on methadone maintenance in the US prison system, 
results at three, six and twelve months after release are now available (Gordon et al. 2008; 
Kinlock et al. 2008; Kinlock et al. 2009). The findings indicate improved drug counselling 
attendance and increased treatment retention if methadone is started before prison release 
compared to counselling only or MMT referral upon release. The group of inmates who 
started methadone before release was also less likely to use illicit opioids or to engage in 
criminal behaviour than the counselling only group. In contrast to our findings, enrolment was 
substantially higher and attrition rather low. 
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Also in the US, 13 multi-site studies targeting drug-involved offenders are currently being 
conducted. The Criminal Justice Drug Abuse Treatment Studies (CJ-DATS) were started in 
2002, funded by the National Institute on Drug Abuse (NIDA) and several supporting 
agencies such as the US Department of Justice and NIAAA (Wexler & Fletcher 2007). This 
large scale initiative includes assessment of offender problems, measurement of progress in 
treatment and recovery, HIV and hepatitis reduction and implementation of planned 
interventions which link criminal justice and drug abuse treatment. Six of the 13 studies apply 
a randomised-controlled design and aim at testing of hypotheses, such as assessing the 
advantages of specifically improved community re-entry strategies compared to usual 
procedures. 
 
4.3. Implications 
4.3.1. Ethics  
The urgent need for more clinical substance abuse research in criminal justice settings has 
been pointed out by Charles O’Brien in a comment on the first large-scale RCT investigating 
methadone for opioid addiction among American prison inmates before release:  
 
“Concern over the rights of prisoners often goes to the point of believing that no person 
under legal restraint can provide free and informed consent to a study. The intention is to 
protect, but the result is that the subjects are deprived of the right to volunteer for studies and 
to receive potential benefits from new treatments.” (O'Brien 2008) 
 
The individuals’ right to choose between treatment and punishment is also considered crucial 
in the drug courts that are increasingly implemented. In this quasi-compulsory treatment 
approach, the individuals’ autonomy is secured by informed consent. A multicentre trial was 
conducted in several European countries to compare quasi-compulsory inpatient treatment 
with a group receiving the same intervention voluntarily, and comparable reductions in drug 
use and criminal behaviour are reported (Uchtenhagen et al. 2008). Another important finding 
is that the participants’ motivation to change was not negatively affected by the choice of 
treatment instead of prison. 
 
The ethics of coercing inmates into treatment have recently been discussed. It has been argued 
that mandated treatment of addiction might be ethical (Caplan 2008), but this argumentation 
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has met objections (Buchman & Russell 2009). Interestingly, when Caplan judged court-
mandated treatment an ethical coercive means, he explicitly referred to naltrexone and argued 
that pharmacotherapy with an antagonist may re-instate the individual’s autonomy, which is 
to some extent impaired by addiction (Caplan 2006). It is doubtful that autonomy can be re-
instated by pharmacotherapy and court-mandated naltrexone treatment has met strong critique 
(Caplan 2007; Hall et al. 2008; Stancliff 2007). In our opinion, any treatment modality should 
be based on free and informed consent which must be carefully implemented especially in 
court-mandated, compulsory or quasi-compulsory treatment. In line with O’Brien’s comment 
we think that achieving informed consent is possible in criminal justice settings. It implies 
that individuals must have understood the possibility to withdraw from treatment at any stage; 
which was found to occur in the prison study. Offering unregistered pharmacotherapy in 
compulsory treatment is unethical. 
 
In the prison study, two substantially different pharmacotherapies among volunteers were 
compared. On the one hand, addictive methadone that needed to be ingested under 
supervision every day. On the other hand, heroin-blocking naltrexone that was surgically 
inserted and not connected to any compulsory aftercare. In contrast to our approach, the other 
three RCTs on oral naltrexone for inmates used a design that might be considered quasi-
compulsory (Brahen et al. 1984; Chan 1996; Cornish et al. 1997). Pharmacotherapy was 
integrated with psychosocial support that enhances external motivation, such as work-release 
and parole including follow-up by criminal justice staff. We aimed at informing as many 
eligible inmates as possible and since many rejected participation, they appeared autonomous 
and capable of making decisions that influence their lives after prison release. Since 
methadone start before release could not be guaranteed, MMT can hardly be considered a 
potent enough incentive to judge our study design quasi-compulsory. Nevertheless, we 
expected methadone to be more attractive than naltrexone implant treatment. Therefore, MMT 
was made available through voluntary group cross-over after the trial’s first six months, but 
still on the condition of an approved application to Norwegian OMT authorities.  
 
The prison study has been criticized (Ruyter et al. 2009). Firstly, it was stated that the 
prisoners might have been subject to coercion by improved access to methadone - which was 
not the case. Secondly, it was argued that the study was unethical because non-participants 
were not receiving study treatment. According to our evaluations, clinical research would be 
impossible if the study treatment should be offered to all possibly interested parties. Further, 
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those who rejected trial participation were systematically informed of the possibility to apply 
for ordinary OMT which is available in Norwegian prisons subject to waiting lists.  
 
4.3.2. Future research with naltrexone implants 
In previous criminal justice research, beneficial effects have been reported for methadone and 
oral naltrexone, but implants have not been used and the two pharmacotherapies have not 
been directly compared. The previous trials show important commonalities with our RCT: 
pharmacological interventions reduce drug use and criminal activity among inmates in prison 
settings and after release. These reductions are also found in RCTs involving individuals in 
the community. Also, as shown in community settings for several decades, agonist 
maintenance is more attractive than naltrexone.  
 
Future studies on naltrexone implants should investigate the blood levels that block clinically 
relevant amounts of heroin; pharmacokinetic studies in healthy volunteers are lacking. 
Longitudinal randomised studies in criminal justice and community settings are needed to 
compare the effects of naltrexone implants and available standard treatment such as OMT. 
Important outcome measures are mortality, heroin and other drug use, time in treatment and 
extent of rehabilitation. Target populations that benefit from naltrexone implant treatment 
need to be defined further. 
 
5. Conclusions 
The systematic review of the literature conducted in 2007 did not find sufficient evidence to 
conclude with the effectiveness of sustained-release naltrexone treatment for opioid 
dependence. However, several RCTs have subsequently reported heroin use reductions during 
naltrexone implant treatment. This finding is supported by cohort studies and case reports. 
The prison study reported in this thesis found naltrexone implants and methadone treatment to 
be of comparable effectiveness in terms of self-reported reductions in heroin and illicit 
benzodiazepine use and criminality. The study is too small to conclude on possible 
advantages of one treatment modality over the other. Further research on pharmacotherapy in 
drug-involved criminal justice populations is urgently needed. Such studies should be planned 
according to the challenges that were met in this study. Access to prison-based methadone 
maintenance in Norway should be facilitated. The effectiveness of sustained-release 
naltrexone to block opioid effects and to prevent high rates of immediate opioid relapse and 
overdose after prison release should be investigated further. 
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